This clinical trial is focused on studying the effects of a medication called Ocrelizumab in patients with Multiple Sclerosis (MS). Multiple Sclerosis is a condition that affects the brain and spinal cord, leading to a range of symptoms such as problems with vision, arm or leg movement, sensation, or balance. The study will compare two forms of administering Ocrelizumab: one is a subcutaneous injection, which means it is injected under the skin, and the other is an intravenous infusion, which means it is given directly into a vein.
The purpose of the study is to investigate how the body processes the subcutaneous form of Ocrelizumab compared to the intravenous form. Participants in the study will receive either the subcutaneous or intravenous form of the medication. The study will monitor various aspects such as the concentration of the medication in the blood, the number of new or enlarging lesions in the brain as seen on an MRI scan, and any side effects that may occur. The study will also look at the presence of antibodies, which are proteins made by the immune system, that might develop in response to the medication.
The study will take place over a period of time, with regular check-ups and assessments to ensure the safety and effectiveness of the treatment. Participants will have their blood tested, undergo MRI scans, and have their vital signs and laboratory test results monitored. The goal is to gather information on how well the subcutaneous form of Ocrelizumab works compared to the intravenous form, and to ensure it is safe for patients with Multiple Sclerosis.



Czechia
Italy
Poland
Spain